{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,31]],"date-time":"2026-10-31T02:07:24Z","timestamp":1793412444344,"version":"4.5.0"},"reference-count":44,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2025,3,31]],"date-time":"2025-03-31T00:00:00Z","timestamp":1743379200000},"content-version":"vor","delay-in-days":30,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/501100013342","name":"NIHR Imperial Biomedical Research Centre","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100013342","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001922","name":"Efficacy and Mechanism Evaluation Programme","doi-asserted-by":"publisher","award":["16\/33\/01"],"award-info":[{"award-number":["16\/33\/01"]}],"id":[{"id":"10.13039\/501100001922","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001922","name":"Efficacy and Mechanism Evaluation Programme","doi-asserted-by":"publisher","award":["08\/99\/08"],"award-info":[{"award-number":["08\/99\/08"]}],"id":[{"id":"10.13039\/501100001922","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001922","name":"Efficacy and Mechanism Evaluation Programme","doi-asserted-by":"publisher","award":["11\/14\/08"],"award-info":[{"award-number":["11\/14\/08"]}],"id":[{"id":"10.13039\/501100001922","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100009128","name":"Research for Patient Benefit Programme","doi-asserted-by":"publisher","award":["PB-PG-0610-22350"],"award-info":[{"award-number":["PB-PG-0610-22350"]}],"id":[{"id":"10.13039\/501100009128","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000272","name":"NIHR","doi-asserted-by":"crossref","award":["NIHR\/CS\/009\/007"],"award-info":[{"award-number":["NIHR\/CS\/009\/007"]}],"id":[{"id":"10.13039\/501100000272","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100000272","name":"NIHR","doi-asserted-by":"crossref","award":["RP-2015-06-018"],"award-info":[{"award-number":["RP-2015-06-018"]}],"id":[{"id":"10.13039\/501100000272","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100000846","name":"Intensive Care Society","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000846","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100007567","name":"Association of Anaesthetists","doi-asserted-by":"publisher","award":["John Snow Anaesthesia Intercalated Award"],"award-info":[{"award-number":["John Snow Anaesthesia Intercalated Award"]}],"id":[{"id":"10.13039\/501100007567","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100011716","name":"British Journal of Anaesthesia","doi-asserted-by":"publisher","award":["John Snow Intercalated Award"],"award-info":[{"award-number":["John Snow Intercalated Award"]}],"id":[{"id":"10.13039\/100011716","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001297","name":"Royal College of Anaesthetists","doi-asserted-by":"crossref","award":["John Snow Intercalated Award"],"award-info":[{"award-number":["John Snow Intercalated Award"]}],"id":[{"id":"10.13039\/501100001297","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Intensive Care Med"],"published-print":{"date-parts":[[2025,3]]},"DOI":"10.1007\/s00134-025-07859-4","type":"journal-article","created":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T21:00:01Z","timestamp":1743541201000},"page":"529-541","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":26,"title":["Metabolic septic shock sub-phenotypes, stability over time and association with clinical outcome"],"prefix":"10.1007","volume":"51","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1846-9160","authenticated-orcid":false,"given":"David B.","family":"Antcliffe","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elsa","family":"Harte","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Humma","family":"Hussain","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beatriz","family":"Jim\u00e9nez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charlotte","family":"Browning","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anthony C.","family":"Gordon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,3,31]]},"reference":[{"key":"7859_CR1","doi-asserted-by":"publisher","first-page":"801","DOI":"10.1001\/jama.2016.0287","volume":"315","author":"M Singer","year":"2016","unstructured":"Singer M, Deutschman CS, Seymour CW et al (2016) The third international consensus definitions for sepsis and septic shock (Sepsis-3). JAMA 315:801\u2013810. https:\/\/doi.org\/10.1001\/jama.2016.0287","journal-title":"JAMA"},{"key":"7859_CR2","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1016\/S0140-6736(19)32989-7","volume":"395","author":"KE Rudd","year":"2020","unstructured":"Rudd KE, Johnson SC, Agesa KM et al (2020) Global, regional, and national sepsis incidence and mortality, 1990\u20132017: analysis for the Global Burden of Disease Study. The Lancet 395:200\u2013211. https:\/\/doi.org\/10.1016\/S0140-6736(19)32989-7","journal-title":"The Lancet"},{"key":"7859_CR3","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1016\/j.molmed.2014.01.007","volume":"20","author":"JC Marshall","year":"2014","unstructured":"Marshall JC (2014) Why have clinical trials in sepsis failed? Trends Mol Med 20:195\u2013203. https:\/\/doi.org\/10.1016\/j.molmed.2014.01.007","journal-title":"Trends Mol Med"},{"key":"7859_CR4","doi-asserted-by":"publisher","first-page":"1141","DOI":"10.1038\/s41591-022-01843-x","volume":"28","author":"DM Maslove","year":"2022","unstructured":"Maslove DM, Tang B, Shankar-Hari M et al (2022) Redefining critical illness. Nat Med 28:1141\u20131148. https:\/\/doi.org\/10.1038\/s41591-022-01843-x","journal-title":"Nat Med"},{"key":"7859_CR5","doi-asserted-by":"publisher","first-page":"328","DOI":"10.1164\/rccm.201608-1685OC","volume":"196","author":"KL Burnham","year":"2017","unstructured":"Burnham KL, Davenport EE, Radhakrishnan J et al (2017) Shared and distinct aspects of the sepsis transcriptomic response to fecal peritonitis and pneumonia. Am J Respir Crit Care Med 196:328\u2013339. https:\/\/doi.org\/10.1164\/rccm.201608-1685OC","journal-title":"Am J Respir Crit Care Med"},{"key":"7859_CR6","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1016\/S2213-2600(16)00046-1","volume":"4","author":"EE Davenport","year":"2016","unstructured":"Davenport EE, Burnham KL, Radhakrishnan J et al (2016) Genomic landscape of the individual host response and outcomes in sepsis: a prospective cohort study. Lancet Respir Med 4:259\u2013271","journal-title":"Lancet Respir Med"},{"key":"7859_CR7","doi-asserted-by":"publisher","first-page":"816","DOI":"10.1016\/S2213-2600(17)30294-1","volume":"5","author":"BP Scicluna","year":"2017","unstructured":"Scicluna BP, van Vught LA, Zwinderman AH et al (2017) Classification of patients with sepsis according to blood genomic endotype: a prospective cohort study. Lancet Respir Med 5:816\u2013826. https:\/\/doi.org\/10.1016\/S2213-2600(17)30294-1","journal-title":"Lancet Respir Med"},{"key":"7859_CR8","doi-asserted-by":"publisher","first-page":"611","DOI":"10.1016\/S2213-2600(14)70097-9","volume":"2","author":"CS Calfee","year":"2014","unstructured":"Calfee CS, Delucchi K, Parsons PE et al (2014) Subphenotypes in acute respiratory distress syndrome: latent class analysis of data from two randomised controlled trials. Lancet Respir Med 2:611\u2013620. https:\/\/doi.org\/10.1016\/S2213-2600(14)70097-9","journal-title":"Lancet Respir Med"},{"key":"7859_CR9","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1136\/THORAX-2023-220538","volume":"79","author":"DB Antcliffe","year":"2024","unstructured":"Antcliffe DB, Mi Y, Santhakumaran S et al (2024) Patient stratification using plasma cytokines and their regulators in sepsis: relationship to outcomes, treatment effect and leucocyte transcriptomic subphenotypes. Thorax 79:515\u2013523. https:\/\/doi.org\/10.1136\/THORAX-2023-220538","journal-title":"Thorax"},{"key":"7859_CR10","doi-asserted-by":"publisher","first-page":"980","DOI":"10.1164\/rccm.201807-1419OC","volume":"199","author":"DB Antcliffe","year":"2019","unstructured":"Antcliffe DB, Burnham KL, Al-Beidh F et al (2019) Transcriptomic signatures in sepsis and a differential response to steroids from the VANISH randomized trial. Am J Respir Crit Care Med 199:980\u2013986. https:\/\/doi.org\/10.1164\/rccm.201807-1419OC","journal-title":"Am J Respir Crit Care Med"},{"key":"7859_CR11","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1164\/rccm.201603-0645OC","volume":"195","author":"KR Famous","year":"2017","unstructured":"Famous KR, Delucchi K, Ware LB et al (2017) Acute respiratory distress syndrome subphenotypes respond differently to randomized fluid management strategy. Am J Respir Crit Care Med 195:331\u2013338. https:\/\/doi.org\/10.1164\/rccm.201603-0645OC","journal-title":"Am J Respir Crit Care Med"},{"key":"7859_CR12","doi-asserted-by":"publisher","first-page":"691","DOI":"10.1016\/S2213-2600(18)30177-2","volume":"6","author":"CS Calfee","year":"2018","unstructured":"Calfee CS, Delucchi KL, Sinha P et al (2018) ARDS subphenotypes and differential response to simvastatin: secondary analysis of a randomized controlled trial. Lancet Respir Med 6:691. https:\/\/doi.org\/10.1016\/S2213-2600(18)30177-2","journal-title":"Lancet Respir Med"},{"key":"7859_CR13","doi-asserted-by":"publisher","first-page":"1054","DOI":"10.1038\/4551054a","volume":"455","author":"JK Nicholson","year":"2008","unstructured":"Nicholson JK, Lindon JC (2008) Systems biology: metabonomics. Nature 455:1054\u20131056. https:\/\/doi.org\/10.1038\/4551054a","journal-title":"Nature"},{"key":"7859_CR14","doi-asserted-by":"publisher","first-page":"376","DOI":"10.3390\/METABO12050376","volume":"12","author":"H Hussain","year":"2022","unstructured":"Hussain H, Vutipongsatorn K, Jim\u00e9nez B, Antcliffe DB (2022) Patient stratification in sepsis: using metabolomics to detect clinical phenotypes, sub-phenotypes and therapeutic response. Metabolites 12:376. https:\/\/doi.org\/10.3390\/METABO12050376","journal-title":"Metabolites"},{"key":"7859_CR15","doi-asserted-by":"publisher","DOI":"10.1097\/CCE.0000000000000478","volume":"3","author":"AJ Rogers","year":"2021","unstructured":"Rogers AJ, Leligdowicz A, Contrepois K et al (2021) Plasma metabolites in early sepsis identify distinct clusters defined by plasma lipids. Crit Care Explor 3:e0478. https:\/\/doi.org\/10.1097\/CCE.0000000000000478","journal-title":"Crit Care Explor"},{"key":"7859_CR16","doi-asserted-by":"publisher","first-page":"1176199","DOI":"10.3389\/FENDO.2023.1176199\/BIBTEX","volume":"14","author":"S Lebedeva","year":"2023","unstructured":"Lebedeva S, Margaryan A, Smolyarchuk E et al (2023) Metabolic effects of vasopressin in pathophysiology of diabetic kidney disease. Front Endocrinol (Lausanne) 14:1176199. https:\/\/doi.org\/10.3389\/FENDO.2023.1176199\/BIBTEX","journal-title":"Front Endocrinol (Lausanne)"},{"key":"7859_CR17","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1097\/SHK.0000000000000851","volume":"48","author":"Z Hajjej","year":"2017","unstructured":"Hajjej Z, Meddeb B, Sellami W et al (2017) Effects of levosimendan on cellular metabolic alterations in patients with septic shock: a randomized controlled pilot study. Shock 48:307. https:\/\/doi.org\/10.1097\/SHK.0000000000000851","journal-title":"Shock"},{"key":"7859_CR18","doi-asserted-by":"publisher","first-page":"R113","DOI":"10.1530\/EJE-21-0553","volume":"185","author":"M Swarbrick","year":"2021","unstructured":"Swarbrick M, Zhou H, Seibel M (2021) Mechanisms in endocrinology: local and systemic effects of glucocorticoids on metabolism: new lessons from animal models. Eur J Endocrinol 185:R113\u2013R129. https:\/\/doi.org\/10.1530\/EJE-21-0553","journal-title":"Eur J Endocrinol"},{"key":"7859_CR19","doi-asserted-by":"publisher","DOI":"10.1016\/J.EBIOM.2023.104771","volume":"96","author":"CI Maushart","year":"2023","unstructured":"Maushart CI, Sun W, Othman A et al (2023) Effect of high-dose glucocorticoid treatment on human brown adipose tissue activity: a randomised, double-blinded, placebo-controlled cross-over trial in healthy men. EBioMedicine 96:104771. https:\/\/doi.org\/10.1016\/J.EBIOM.2023.104771","journal-title":"EBioMedicine"},{"key":"7859_CR20","doi-asserted-by":"publisher","first-page":"A140","DOI":"10.1111\/ANAE.16193","volume":"79","author":"E Harte","year":"2024","unstructured":"Harte E, Hussain H, Jimenez B et al (2024) Metabolic sub-phenotypes in sepsis: association with outcomes and trajectory over time. Anaesthesia 79:A140. https:\/\/doi.org\/10.1111\/ANAE.16193","journal-title":"Anaesthesia"},{"key":"7859_CR21","doi-asserted-by":"publisher","first-page":"A4994","DOI":"10.1164\/AJRCCM-CONFERENCE.2024.209.1_MEETINGABSTRACTS.A4994","volume":"209","author":"DB Antcliffe","year":"2024","unstructured":"Antcliffe DB, Harte E, Hussain H et al (2024) Validation of septic shock metabolic phenotypes, trajectory over time and association with outcome. Am J Respir Crit Care Med 209:A4994. https:\/\/doi.org\/10.1164\/AJRCCM-CONFERENCE.2024.209.1_MEETINGABSTRACTS.A4994","journal-title":"Am J Respir Crit Care Med"},{"key":"7859_CR22","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1609409","author":"AC Gordon","year":"2016","unstructured":"Gordon AC, Perkins GD, Singer M, McAuley RMLO DF, Santhakumaran S, Mason AJ, Cross M, Al-Beidh F, Best-Lane J, Brealey D, Nutt CL, McNamee JJ, Reschreiter H, Breen A, Liu KD, Ashby D (2016) Levosimendan for the prevention of acute organ dysfunction in sepsis. N Engl J Med. https:\/\/doi.org\/10.1056\/NEJMoa1609409","journal-title":"N Engl J Med"},{"key":"7859_CR23","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1001\/jama.2016.10485","volume":"316","author":"AC Gordon","year":"2016","unstructured":"Gordon AC, Mason AJ, Thirunavukkarasu N et al (2016) Effect of early vasopressin vs norepinephrine on kidney failure in patients with septic shock: the VANISH randomized clinical trial. JAMA 316:509\u2013518. https:\/\/doi.org\/10.1001\/jama.2016.10485","journal-title":"JAMA"},{"key":"7859_CR24","doi-asserted-by":"publisher","first-page":"244","DOI":"10.1016\/j.ebiom.2017.03.034","volume":"18","author":"D Antcliffe","year":"2017","unstructured":"Antcliffe D, Jim\u00e9nez B, Veselkov K et al (2017) Metabolic profiling in patients with pneumonia on intensive care. EBioMedicine 18:244\u2013253. https:\/\/doi.org\/10.1016\/j.ebiom.2017.03.034","journal-title":"EBioMedicine"},{"key":"7859_CR25","unstructured":"Burnham K, Antcliffe D (2022) SRS endotype assignment of septic shock patients from the VANISH randomised trial. In: ArrayExpress. https:\/\/www.ebi.ac.uk\/biostudies\/arrayexpress\/studies\/E-MTAB-7581"},{"key":"7859_CR26","doi-asserted-by":"publisher","DOI":"10.1093\/nar\/gkv007","volume":"43","author":"ME Ritchie","year":"2015","unstructured":"Ritchie ME, Phipson B, Wu D et al (2015) Limma powers differential expression analyses for RNA-sequencing and microarray studies. Nucleic Acids Res 43:e47. https:\/\/doi.org\/10.1093\/nar\/gkv007","journal-title":"Nucleic Acids Res"},{"key":"7859_CR27","volume-title":"R: a language and environment for statistical computing","author":"R Core Team","year":"2015","unstructured":"R Core Team (2015) R: a language and environment for statistical computing. R Foundation for Statistical Computing"},{"key":"7859_CR28","doi-asserted-by":"publisher","first-page":"882","DOI":"10.1016\/j.jcrc.2014.05.003","volume":"29","author":"DW Park","year":"2014","unstructured":"Park DW, Kwak DS, Park YY et al (2014) Impact of serial measurements of lysophosphatidylcholine on 28-day mortality prediction in patients admitted to the intensive care unit with severe sepsis or septic shock. J Crit Care 29:882. https:\/\/doi.org\/10.1016\/j.jcrc.2014.05.003. (e5\u201311)","journal-title":"J Crit Care"},{"key":"7859_CR29","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1038\/nm989","volume":"10","author":"JJ Yan","year":"2004","unstructured":"Yan JJ, Jung JS, Lee JE et al (2004) Therapeutic effects of lysophosphatidylcholine in experimental sepsis. Nat Med 10:161\u2013167. https:\/\/doi.org\/10.1038\/nm989","journal-title":"Nat Med"},{"key":"7859_CR30","doi-asserted-by":"publisher","first-page":"743","DOI":"10.1164\/RCCM.201209-1718OC","volume":"187","author":"P Kruger","year":"2013","unstructured":"Kruger P, Bailey M, Bellomo R et al (2013) A multicenter randomized trial of atorvastatin therapy in intensive care patients with severe sepsis. Am J Respir Crit Care Med 187:743\u2013750. https:\/\/doi.org\/10.1164\/RCCM.201209-1718OC","journal-title":"Am J Respir Crit Care Med"},{"key":"7859_CR31","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1186\/2197-425X-2-9","volume":"2","author":"J Morel","year":"2014","unstructured":"Morel J, Singer M (2014) Statins, fibrates, thiazolidinediones and resveratrol as adjunctive therapies in sepsis: could mitochondria be a common target? Intensive Care Med Exp 2:9. https:\/\/doi.org\/10.1186\/2197-425X-2-9","journal-title":"Intensive Care Med Exp"},{"key":"7859_CR32","doi-asserted-by":"publisher","first-page":"2341","DOI":"10.1056\/NEJMOA2309995","volume":"389","author":"The REMAP-CAP Investigators","year":"2023","unstructured":"The REMAP-CAP Investigators (2023) Simvastatin in critically Ill patients with Covid-19. N Engl J Med 389:2341\u20132354. https:\/\/doi.org\/10.1056\/NEJMOA2309995","journal-title":"N Engl J Med"},{"key":"7859_CR33","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1177\/0300060520953684\/SUPPL_FILE\/SJ-PDF-1-IMR-10.1177_0300060520953684.PDF","volume":"48","author":"C Wang","year":"2020","unstructured":"Wang C, Han D, Feng X, Wu J (2020) Omega-3 fatty acid supplementation is associated with favorable outcomes in patients with sepsis: an updated meta-analysis. J Int Med Res 48:1\u201313. https:\/\/doi.org\/10.1177\/0300060520953684\/SUPPL_FILE\/SJ-PDF-1-IMR-10.1177_0300060520953684.PDF","journal-title":"J Int Med Res"},{"key":"7859_CR34","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1186\/S13054-023-04387-9","volume":"27","author":"SM Pienkos","year":"2023","unstructured":"Pienkos SM, Moore AR, Guan J et al (2023) Effect of total cholesterol and statin therapy on mortality in ARDS patients: a secondary analysis of the SAILS and HARP-2 trials. Crit Care 27:126. https:\/\/doi.org\/10.1186\/S13054-023-04387-9","journal-title":"Crit Care"},{"key":"7859_CR35","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1016\/j.plipres.2020.101068","volume":"80","author":"S Ting Tan","year":"2020","unstructured":"Ting Tan S, Ramesh T, Toh XR, Nguyen LN (2020) Emerging roles of lysophospholipids in health and disease. Prog Lipid Res 80:163\u20137827. https:\/\/doi.org\/10.1016\/j.plipres.2020.101068","journal-title":"Prog Lipid Res"},{"key":"7859_CR36","doi-asserted-by":"publisher","DOI":"10.3389\/FCELL.2022.941914\/FULL","volume":"10","author":"S Jeong","year":"2022","unstructured":"Jeong S, Kim B, Byun DJ et al (2022) Lysophosphatidylcholine alleviates acute lung injury by regulating neutrophil motility and neutrophil extracellular trap formation. Front Cell Dev Biol 10:941914. https:\/\/doi.org\/10.3389\/FCELL.2022.941914\/FULL","journal-title":"Front Cell Dev Biol"},{"key":"7859_CR37","doi-asserted-by":"publisher","first-page":"2840","DOI":"10.3390\/toxins6092840","volume":"6","author":"J Rolin","year":"2014","unstructured":"Rolin J, Vego H, Maghazachi AA (2014) Oxidized lipids and lysophosphatidylcholine induce the chemotaxis, up-regulate the expression of CCR9 and CXCR4 and abrogate the release of IL-6 in human monocytes. Toxins (Basel) 6:2840\u20132856. https:\/\/doi.org\/10.3390\/toxins6092840","journal-title":"Toxins (Basel)"},{"key":"7859_CR38","doi-asserted-by":"publisher","first-page":"558","DOI":"10.1016\/j.jhep.2022.10.031","volume":"78","author":"FM Trovato","year":"2023","unstructured":"Trovato FM, Zia R, Artru F et al (2023) Lysophosphatidylcholines modulate immunoregulatory checkpoints in peripheral monocytes and are associated with mortality in people with acute liver failure Cirrhosis and Liver Failure. J Hepatol 78:558\u2013573. https:\/\/doi.org\/10.1016\/j.jhep.2022.10.031","journal-title":"J Hepatol"},{"key":"7859_CR39","doi-asserted-by":"publisher","first-page":"973","DOI":"10.1164\/RCCM.202308-1321OC\/SUPPL_FILE\/DISCLOSURES.PDF","volume":"209","author":"O Chouchane","year":"2024","unstructured":"Chouchane O, Schuurman AR, Reijnders TDY et al (2024) The plasma lipidomic landscape in patients with sepsis due to community-acquired pneumonia. Am J Respir Crit Care Med 209:973\u2013986. https:\/\/doi.org\/10.1164\/RCCM.202308-1321OC\/SUPPL_FILE\/DISCLOSURES.PDF","journal-title":"Am J Respir Crit Care Med"},{"key":"7859_CR40","doi-asserted-by":"publisher","first-page":"364","DOI":"10.1097\/MOL.0000000000000630","volume":"30","author":"M Kajikawa","year":"2019","unstructured":"Kajikawa M, Higashi Y (2019) Triglycerides and endothelial function: molecular biology to clinical perspective. Curr Opin Lipidol 30:364\u2013369. https:\/\/doi.org\/10.1097\/MOL.0000000000000630","journal-title":"Curr Opin Lipidol"},{"key":"7859_CR41","doi-asserted-by":"publisher","first-page":"792","DOI":"10.1161\/ATVBAHA.107.159749","volume":"28","author":"A Alipour","year":"2008","unstructured":"Alipour A, Van Oostrom AJHHM, Izraeljan A et al (2008) Leukocyte activation by triglyceride-rich lipoproteins. Arterioscler Thromb Vasc Biol 28:792\u2013797. https:\/\/doi.org\/10.1161\/ATVBAHA.107.159749","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"7859_CR42","doi-asserted-by":"publisher","first-page":"1360","DOI":"10.1007\/s00134-023-07239-w","volume":"49","author":"RBE Van Amstel","year":"2023","unstructured":"Van Amstel RBE, Kennedy JN, Scicluna BP et al (2023) Uncovering heterogeneity in sepsis: a comparative analysis of subphenotypes on behalf of the MARS consortium. Intensive Care Med 49:1360\u20131369. https:\/\/doi.org\/10.1007\/s00134-023-07239-w","journal-title":"Intensive Care Med"},{"key":"7859_CR43","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1007\/S00134-022-06905-9","volume":"49","author":"C Cleasby","year":"2023","unstructured":"Cleasby C, Marshall T, Gordon AC et al (2023) The effect of vasopressin and hydrocortisone on cytokine trajectories. Intensive Care Med 49:241. https:\/\/doi.org\/10.1007\/S00134-022-06905-9","journal-title":"Intensive Care Med"},{"key":"7859_CR44","doi-asserted-by":"publisher","first-page":"1392","DOI":"10.1007\/s00134-019-05731-w","volume":"45","author":"DB Antcliffe","year":"2019","unstructured":"Antcliffe DB, Santhakumaran S, Orme RML et al (2019) Levosimendan in septic shock in patients with biochemical evidence of cardiac dysfunction: a subgroup analysis of the LeoPARDS randomised trial. Intensive Care Med 45:1392\u20131400. https:\/\/doi.org\/10.1007\/s00134-019-05731-w","journal-title":"Intensive Care Med"}],"updated-by":[{"DOI":"10.1007\/s00134-026-08524-0","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2026,6,11]],"date-time":"2026-06-11T00:00:00Z","timestamp":1781136000000}}],"container-title":["Intensive Care Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00134-025-07859-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00134-025-07859-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00134-025-07859-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,30]],"date-time":"2026-06-30T05:40:28Z","timestamp":1782798028000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00134-025-07859-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3]]},"references-count":44,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2025,3]]}},"alternative-id":["7859"],"URL":"https:\/\/doi.org\/10.1007\/s00134-025-07859-4","relation":{},"ISSN":["0342-4642","1432-1238"],"issn-type":[{"value":"0342-4642","type":"print"},{"value":"1432-1238","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3]]},"assertion":[{"value":"20 December 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 March 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 March 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 June 2026","order":5,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Update","order":6,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Figures 1-3 and the Electronic Supplementary Material were mistakenly given in incomplete versions.","order":7,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 June 2026","order":8,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":9,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A Correction to this paper has been published:","order":10,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1007\/s00134-026-08524-0","URL":"https:\/\/doi.org\/10.1007\/s00134-026-08524-0","order":11,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"ACG reports that he has received speaker fees from Orion Corporation Orion Pharma and Amomed Pharma. He has consulted for Ferring Pharmaceuticals, Tenax Therapeutics, and received grant support from Orion Corporation Orion Pharma, and Tenax Therapeutics with funds paid to his institution. All other authors declare no conflict of interest directly applicable to this research.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}}]}}